See also: New and Experimental HIV Drugs and Treatments
General Information
- Ritonavir (Norvir) (AIDS InfoNet) and Spanish version
- Norvir (Poz)
- Combination Medications (AIDS InfoNet) and Spanish version
- Tybost (Poz)
- Cobicistat (COBI) (Test Positive Aware Network)
Selected Recent Articles
- Of Meds, ‘Boosters’ Most Likely to Clash With Recreational Drugs. (September 2015, Poz)
- HIV-treatment ‘booster drugs’ are most likely to have dangerous interactions with methamphetamine, mephedrone, MDMA and ketamine. (August 2015, AIDSmap)
- Cobicistat Safe for HIV-Positive Patients with Mild to Moderate Renal Impairment. (October 2014, TheBody)
- Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP. (September/October 2014, HIV Treatment Bulletin)
- New FDA HIV Drug Approvals Unlikely to Have Much Impact, Unless . . . (September 2014, Journal Watch)
- Tybost (Cobicistat) and Vitekta (Elvitegravir) Approved as Individual HIV Drugs. (September 2014, TheBody)
- HIV/AIDS Update: Approval of Tybost (cobicistat) 150 mg tablets. (September 2014, U.S. Food and Drug Administration)
- FDA Approves HIV Treatment Boosting Agent Tybost (Cobicistat) (September 2014, Poz)
- BMS Files for FDA Approval of Reyataz/Cobicistat Combo Pill. (April 2014, Poz)